Impact BioMedical, Inc. (IBO) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Impact BioMedical, Inc. (IBO) has a cash flow conversion efficiency ratio of 0.225x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.99 Million) by net assets ($-8.85 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Impact BioMedical, Inc. balance sheet quality to measure how much of total assets are equity-financed.
Impact BioMedical, Inc. - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how Impact BioMedical, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Impact BioMedical, Inc. (IBO) cash earnings ratio to evaluate the quality of earnings relative to operating cash generation.
Impact BioMedical, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Impact BioMedical, Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Eternit S.A
SA:ETER3
|
0.061x |
|
Daelim B&Co
KO:005750
|
-0.002x |
|
Theranexus SA
PA:ALTHX
|
-0.305x |
|
DreamCIS Inc
KQ:223250
|
0.023x |
|
Intrum Justitia AB
ST:INTRUM
|
0.059x |
|
Enwell Energy plc
F:RHN
|
-0.003x |
|
Hastings Technology Metals Ltd
AU:HAS
|
-0.035x |
|
Yufo Electronics Co Ltd
TWO:6194
|
0.045x |
Annual Cash Flow Conversion Efficiency for Impact BioMedical, Inc. (2017–2024)
The table below shows the annual cash flow conversion efficiency of Impact BioMedical, Inc. from 2017 to 2024. For the full company profile with market capitalisation and key ratios, see market value of Impact BioMedical, Inc..
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $7.24 Million | $-5.64 Million | -0.779x | -671.98% |
| 2023-12-31 | $28.26 Million | $-2.85 Million | -0.101x | +23.95% |
| 2022-12-31 | $32.67 Million | $-4.33 Million | -0.133x | +87.98% |
| 2021-12-31 | $2.94 Million | $-3.25 Million | -1.104x | -610.22% |
| 2020-12-31 | $-5.28K | $-1.14K | 0.216x | +116.83% |
| 2019-12-31 | $94.89K | $-121.98K | -1.286x | -251.97% |
| 2018-12-31 | $197.12K | $-71.99K | -0.365x | +66.34% |
| 2017-12-31 | $295.22K | $-320.34K | -1.085x | -- |
About Impact BioMedical, Inc.
Impact BioMedical Inc. discovers, develops, and commercializes products and technologies to address unmet needs in human healthcare and wellness for specialty biopharmaceuticals, antivirals, antimicrobials, consumer healthcare, and wellness products in the United States. The company provides Linebacker, a platform of small molecule electrophilically enhanced polyphenol compounds with application … Read more